The use of [3H](-)-DO 710 as selective dopaminergic ligand for binding and autoradiographic studies.
DO 710, a benzamide derivative previously shown to display a dopamine antagonistic potency superior to that of sulpiride, was 3H-labeled. Its use as radioligand was assessed in membrane binding and autoradiographic studies. The compound displayed relatively high affinity (Kd 2 nM) and pronounced selectivity for dopamine receptors (distinct from D-1 receptors) as well as low non-specific binding particularly evidenced in autoradiographic experiments. Hence [3H](-)-DO 710 displays distinct technical advantages over commonly used dopaminergic radioligands.
D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000378:metabolism; D004294:Domperidone / Q000378:metabolism; D005615:Freezing; D066298:In Vitro Techniques; D007700:Kinetics; D008024:Ligands; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000378:metabolism; D014316:Tritium
D008024:Ligands; D011954:Receptors, Dopamine; D014316:Tritium; D013134:Spiperone; C044629:DO 710; D004294:Domperidone; D013469:Sulpiride